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INTRODUCTION

P
roliferative vitreoretinopathy (PVR), which occurs in 40%-60% of patients with open globe injuries, is the primary factor in causing recurrent retinal detachment following retinal reattachment surgery and tractional retinal detachment after ocular trauma [1] . PVR is a severe, visionthreatening disorder. PVR will induce worse vision in eyes and is wherefore considered as the primary cause of vision loss [2] . Despite advances in therapeutic approaches and vitreoretinal surgery for PVR management, PVR remains an intractable clinical problem [3] . The exact mechanisms responsible for PVR remain unclear, but it is widely accepted that in its pathogenesis, inflammation is significant [4] . Ocular trauma causes increased inflammation and cytokine production, which increases the occurrence of PVR [5] . Fundamental research on the pathogenesis of PVR on cytokines and growth factors provide types of therapeutic target for blocking the cellular events that contribute to this disease. Tumor necrosis factor-α (TNF-α), which is a very prominent inflammatory cytokine, is secreted in response to trauma, infection, and inflammation [6] . It is a key mediator of ocular inflammation and its interactions with the retinal pigment epithelium (RPE) cell that initiates PVR [7] . TNF-α was found to have a causative role in PVR as it can act on the RPE and wherefore consequently induces changes in cellular morphologies into fibroblastic cells. Additionally, if TNF-α is combined with other growth factors, a strong synergistic effect can be induced to form epithelial-mesenchymal transition (EMT)-associated fibrotic focus. Etanercept (rhTNFR-Ig, Enbrel ® ), a TNF-α inhibitor, can bind to TNF-α and therefore functions as a decoy receptor. It was the first biological disease-modifying antirheumatic drug (bDMARD) and the first fusional monoclonal antibody against TNF-α in immune systematic disease, such as juvenile idiopathic arthritis, psoriatic arthritis or plaque psoriasis, ankylosing spondylitis, and rheumatoid arthritis [8] [9] . For patients with noninfective autoimmune uveitis, etanercept is a key costeffective treatment option [10] . Etanercept could play a potential role preventing inflammation changes involved in the PVR, which remains unknown. This study utilized an animal model to assess the effect of etanercept in the treatment of traumainduced PVR. 
MATERIALS AND METHODS
Groups and Traumatic Proliferative Vitreoretinopathy Model
The rabbits were equally and randomly divided into normal group (n=8), PVR model group with sterile watertreated and etanercept-treated group (n=24). Levofloxacin eye drops (0.5%, Santen, Japan) were used three days before and after the intravitreal injection and surgical procedure. The left eyes of normal group rabbits were intravitreal injected with 0.1 mL of sterile water. To assess the security of intravitreal injection of etanercept, the right eyes of normal group rabbits were injected intravitreally with 0.1 mL (12.5 mg/mL, diluted with sterile water for injection) etanercept under general and topical anaesthesia. Traumatic PVR was induced in rabbit of PVR model group and etanercept-treated group as described follows. PVR model group received an additional intravitreal injection of 0.1 mL sterile water 72h after the sclerotomies were sutured. The left eye of etanercept-treated group rabbits were received an additional intravitreal injection of 0.1 mL etanercept (12.5 mg/mL, diluted with sterile water for injection) 72h after the sclerotomies were sutured. The concentrations were chosen based on the preliminary experiment. 
Fundus Photography and B-scan
The fundus was imaged using the digital fundus camera (Nidek, AFC-330, Japan)
10, 20, and 30d after intravitreal injection. Rats cataract or endophthalmitis were excluded from the protocol. The B-scan ultrasonography (ACCUTOME, USA) was performed simultaneously. Proliferative responses were assessed in accordance with these scales: 0, no proliferative response;
1, vitreous haze, vitreous strands; 2, epiretinal membrane formation with retinal folds; and 3, white dense membrane covering the retina with localized retinal detachments and retinal folds [11] . 
Histopathological Examination Two rabbits in PVR model
group, etanercept-treated group (10, 20 , and 30d after trauma respectively) and two rabbits normal group (15d after intravitreal injection) were randomly selected and euthanized.
The left eyes of PVR model group and etanercept-treated group, both eyes of normal group were enucleated, fixed in 10% formalin, all of which were then embedded in paraffin at room temperature. The paraffin-embedded eyes were cut into sections of 4-µm horizontally-thickness via the eye optic disk, which were subsequently fixed on slides. Hematoxylin-eosin (HE) was utilized to stain the sections to observe the abnormal blood vessel growth, the presence of retinal fold, the epiretinal membrane formation, as well as the disruption in the inner retina (from the inner plexiform layer to the inner limiting membrane). A biological microscope (MoticBA400Digital, Fujian, China) was used to perform microscopic analysis at 40× magnification.
Reverse Transcriptase-Polymerase Chain Reaction Analysis
Six rabbits in PVR model group, etanercept-treated group Western Blotting Tissue was lysed with RIPA lysis buffer (1:10) and lysate was incubated on ice for 15min, then was subject to centrifugal clarification at 14 000×g, 4℃, for 10min
(TGL-16G-A, Anke, Shanghai, China). BCA reagents (Thermo Scientific) were used to determine protein concentration.
The supernatant was run on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel, which was then transferred to a nitrocellulose membrane. Blocking solution [10 g skim milk in 20 mL 1 mol/L Tris-buffered saline and 150 mL 0.1% Tween 20 (TBST)] was used to incubate the membranes for 1h at room temperature, which were subsequently incubated with primary antibody to TNF-α, TGF-β, CTGF, followed by anti-IgG horseradish peroxidaseconjugated secondary antibody. Enhanced chemiluminescence (ECL, BL520A, Thermo, USA) was used to detect the blots. Quantity One software (Bio-Rad, Richmond, CA, US) was used to quantify each band density, which was then normalized to β-actin. All immunoblot analyses were repeated in triplicate, to obtain similar results.
Statistical Evaluation
The quantitative data were expressed as the means±standard deviation (SD Figure 1A ) and right eyes ( Figure 1E ) of normal group. Different grades of PVR were observed in PVR model group. Fundus photographs of the injured eye demonstrated injuries in the retina, which caused vitreous haze, vitreous strands, and epiretinal hemorrhage 10d after the injury ( Figure 1B ).
Epiretinal membrane which covered the retinas by localized retinal detachments and retinal folds were observed 20d after the injury ( Figure 1C ). Epiretinal membrane formation, wrinkling of the retina, and extensive retinal detachment were observed 30d after injury ( Figure 1D ). The fundus photography of the rabbits in etanercept-treated group did not experience these severe changes. Epiretinal hemorrhages and mild vitreous haze were observed 10d after injury ( Figure 1F ). Slight focal contraction and moderate vessel tortuosity, with no apparent retinal detachment or severe retinal folds, were observed in the eyes ( Figure 1G and 1H) . Examinations of PVR model group and etanercept-treated group demonstrated a varied degree of PVR, with cyclitic membrane formation induced by retinal traction up into the wound. We performed B-scans in all rabbits and noted changes in vitreous and folding of the detached retina. In stage 0, images of B-scan were normal (Figure 2A ). The vitreous haze was obvious in stage 1, and funicular echo was not observed ( Figure 2B ). The funicular echo connected to the retina was detected in stage 2 and local detachment was not seen ( Figure 2C ). The surface of the retinal was not smooth in stage 3, with significant vitreous traction and retinal detachment ( Figure 2D ). Proliferative responses were evaluated according to fundus images and B-scan. An eye which presented with stage 2 or greater was considered retinal detachment, whose incidences were 0 in normal group, 2 (25%) on 10d after intravitreal injection in PVR model group (P-10d), 6 (75%) on 20d (P-20d), 7 (87.5%) on 30d (P-30d); 0 on 10d after intravitreal injection in etanercept-treated group (T-10d), 2 (25%) on Table 1) . The difference among the three groups at different time points was statistical significance (P=0.014). Significant differences were found in the retinal detachment rate between PVR model group and etanercept-treated group at different time points (P=0.027).
Histopathology Demonstrated PVR Prevention in Etanercept-treated Eyes
The retinas were normal and fully attached in the left ( Figure 3A ) and right eyes ( Figure 3E ) of normal group, where the photoreceptor layer and the RPE were intact. PVR model group had HE-stained frozen sections with clearly marked proliferative membranes as well as the retinal detachment between the sensory retinas and RPE, along with destructed retinas. The PVR process was observed in PVR model group at different time points after injury. And HE staining of retinal tissue section showed different pathological changes according to the grades. In stage 1, attached retina, but epiretinal membrane was began to form and local retinal fold was observed ( Figure 3B ). In stage 2, epiretinal membrane, retinal detachment, the damaged photoreceptor layer and the RPE, and the normal arrangement of the inner nuclear layer is lost ( Figure 3C ). In stage 3, epiretinal membrane was thickening and obvious traction, retinal detachment was significant ( Figure  3D ). The retinal folds, detachment, or epiretinal membrane formation was absent in etanercept-treated group, but the smooth surface of retina was absent ( Figure 3F ) and there was posterior vitreous detachment. The localized retinal separation mimicked pathological retinal detachment, however there was no obvious pathological cause (like fibrosis) ( Figure 3G and 3H). The histological eyes sections further supported the clinical observations. High Expression of TNF-α in Traumatic PVR and Etanercept Downregulates the Expression of CTGF and TGF-β Reverse transcriptase-PCR (RT-PCR) was conducted in this research to assess the expression of the TNF-α and the CTGF. Quality RNA was obtained from six samples in and separation with loss of the retinal pigment epithelial-photoreceptors interface (long arrow) was observed; E: Normal eyes after etanercept intravitreal injection, the retinal histology is normal; F-H: The signs of fibrotic changes were absence in etanercept-treated group. Vitreous strands and traction (arrow) on the retina is slight, the smooth surface of retina was absent. Figure 5C ) and TGF-β ( Figure  5D ) compared with PVR model group rabbits at all time points (P<0.05).
Collectively, these results demonstrate that etanercept can directly blind TNF-α protein and inhibit the further biological effect of it. This preventation is associated with the etanercept therapeutic effect on PVR. DISCUSSION PVR is an inflammatory fibrotic disease characterized by proliferation and migration of ectopic cells in the periretinal and/or vitreous area when the trauma or retina is broken. Formation of the membranes traction in periretinal areas causes rhegmatogenous retinal detachments [12] [13] . The dynamic wound-healing process following tissue injury, including modulation of scar, proliferation, and inflammation, either takes an abnormal path with protracted wound healing, or goes through normal ocular wound healing with tissue remodeling and repair [14] . TNF-α, a cytokine which can promote inflammation, was studied as a promoter of PVR [15] . TNF-α was found in epiretinal membranes of patients and the research animals with PVR, with positive TNF-α staining both intracellularly and in the extracellular matrix [16] [17] [18] . TNF-α plays a causative role within PVR, as it can act on RPE and wherefore induces variations among the cellular morphology into fibroblastic cells. It seems that an interplay exists between matrix proteins, growth factors, and various cytokines [19] . The combination of TNF-α and TGF-β1, fibroblast growth factor (FGF), and CTGF has strong synergistic effects that induces EMT associated fibrotic focus formation [20] [21] . This fundamental understanding aids to identify various adjunct agents blocking the cell events which are intrinsic to the PVR [14] . Subcutaneous etanercept was the first bDMARD, which is now commercially available as the first TNF inhibitor approved to cure rheumatic diseases [9] .
We established a PVR model in rabbits, in which intravitreal injures were induced. To clinically mimic the PVR etiopathogenesis, the PVR model was developed by inciting retinal injury on the upper lateral quadrant of the eye behind the limbus at a fixed distance (3-5 mm), which was commonly met in clinical settings. In most cases, traumatic patients cannot receive therapy or operations immediately, where operation is typically performed a few hours later. The suture was performed at 4h after trauma. Etanercept reduces the inflammatory effect of TNF-α and is used clinically to treat several autoimmune diseases. The TNF-α is shown to take a key role in development of many ocular diseases, e.g. diabetic retina ischemia [22] , retinopathy [23] , glaucoma [24] , and retina degenerative diseases [25] , where anti TNF drug is a potential therapy for diseases. The ocular topical use of a TNF-α inhibitor was thought to circumvent these adverse systemic side effects. Adalimumab injecting (a TNF-α inhibitors, at a dose up to 2.5 mg) into vitreous bodies of healthy rabbits, is not toxic to the rabbit retina [26] . There were no side effects observed of etanercept (12.5 mg/mL) in the intravitreal injection. Systemic or topical infection was an absolute contraindication for the TNF-α inhibitors, so we performed the vitreous injection three days after trauma to exclude endophthalmitis. Early treatment of etanercept blocked retinal damages induced by trauma and wherefore maintained a more intact retinal structure than the saline-treated rabbits. The retina structure seemed to be stable 10d after the trauma, but inflammation was initiated, which was demonstrated in the retinal tissue in the strong expression of TNF-α. This inflammatory environment caused apoptosis as well as appearances of fibroblastic cells, which could consequently result in severe retina damage over time. The TNF-α provoked morphological variations in the RPE, which demonstrated a gain of spindle cell morphology and a lack of intercellular junctions. The early blockage of the local inflammatory signs via etanercept could preserve cellular viability against apoptosis and therefore decreased the expression of TNF-α and CTGF, thus rendering the retinal structure more intact. The TNF-α and CTGF were the predominant cytokines as well as a growth factor in the PVR pathogenesis. The early modulation of the inflammation via etanercept likely reduced the potential for PVR development in animals. Recent research states that CTGF is expressed locally in PVR eyes [27] . In this study, expression of CTGF mRNA was evaluated, which demonstrated that, compared to normal rabbit retina, CTGF mRNA expression was increased in the PVR retina. The results in this work demonstrate that etanercept can be potentially utilized in intravitreal therapy as a secure method to prevent PVR induced by ocular injuries. To assess the clinical application of etanercept, further clinical study is required. 
